View Exam | PowerPak

1. Randomized trials of heart failure treatments have demonstrated significant reductions in mortality in patients with:

A. preserved ejection fraction B. improved ejection fraction C. mid- or borderline ejection fraction D. reduced ejection fraction

2. Based on the 2016 Focused Update heart failure guideline, the use of an angiotensin receptor/neprilysin inhibitor (ARNI) is indicated for:

A. patients who do not tolerate an ACE inhibitor or an ARB B. as an add-on to an ACE inhibitor or an ARB in patients who need additional symptom relief C. patients who tolerate an ACE inhibitor or an ARB but who remain symptomatic D. patients with Class IV heart failure

3. In which of the following conditions can use of an ARNI be considered?

A. creatinine clearance < 50 ml/min B. history of angioedema on an ACE inhibitor C. concomitant use of an ACE inhibitor D. history of hypersensitivity to any component of LCZ696

4. The recommended washout period in patients on an ACE inhibitor who are prescribed the fixed combination sacubitril and valsartan is:

A. 12 hours B. 24 hours C. 36 hours D. variable based on the size of the ACE inhibitor dose

5. Which of the following conditions would rule out the use of ivabradine in patients with heart failure?

A. stable NYHA class II-III B. blood pressure < 90/50 mmHg C. ejection fraction ≤ 35% D. resting heart rate ≥ 70 bpm

6. The target heart rate in patients with heart failure treated with ivabradine is:

A. < 50 bpm B. 50-60 bpm C. ≥ 70 bpm D. titrated to lowest tolerated heart rate

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Randomized trials of heart failure treatments have demonstrated significant reductions in mortality in patients with:

2. Based on the 2016 Focused Update heart failure guideline, the use of an angiotensin receptor/neprilysin inhibitor (ARNI) is indicated for:

3. In which of the following conditions can use of an ARNI be considered?

4. The recommended washout period in patients on an ACE inhibitor who are prescribed the fixed combination sacubitril and valsartan is:

5. Which of the following conditions would rule out the use of ivabradine in patients with heart failure?

6. The target heart rate in patients with heart failure treated with ivabradine is:

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Randomized trials of heart failure treatments have demonstrated significant reductions in mortality in patients with:

2. Based on the 2016 Focused Update heart failure guideline, the use of an angiotensin receptor/neprilysin inhibitor (ARNI) is indicated for:

3. In which of the following conditions can use of an ARNI be considered?

4. The recommended washout period in patients on an ACE inhibitor who are prescribed the fixed combination sacubitril and valsartan is:

5. Which of the following conditions would rule out the use of ivabradine in patients with heart failure?

6. The target heart rate in patients with heart failure treated with ivabradine is:

« Return to Activity

Customers who Purchased
this Activity also Purchased